Hexokinase 2-Mediated Warburg Effect Is Required for PTEN- and p53-Deficiency-Driven Prostate Cancer Growth

Cell Reports

Volumn 8, Issue 5, 2014, Pages 1461-1474

  Wang, Lei ^a   Xiong, Hua ^a   Wu, Fengxia ^a   Zhang, Yingjie ^a   Wang, Ji ^a   Zhao, Liyan ^a   Guo, Xiaolan ^a   Chang, Li Ju ^a   Zhang, Yong ^b   You, M James ^c   Koochekpour, Shahriar ^d   Saleem, Mohammad ^a   Huang, Haojie ^e   Lu, Junxuan ^b   Deng, Yibin ^a  

^a University of Minnesota Hormel Institute   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d ROSWELL PARK CANCER INSTITUTE   (United States)

^e MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEXOKINASE; HEXOKINASE 2; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN COMPLEX 1; MESSENGER RNA; MICRORNA 143; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; UNCLASSIFIED DRUG; CARRIER PROTEIN; EIF4EBP1 PROTEIN, MOUSE; HEXOKINASE 2, MOUSE; MECHANISTIC TARGET OF RAPAMYCIN COMPLEX 1; MULTIPROTEIN COMPLEX; PHOSPHOPROTEIN; PTEN PROTEIN, MOUSE; TARGET OF RAPAMYCIN KINASE;

AEROBIC GLYCOLYSIS; AEROBIC METABOLISM; ANIMAL CELL; ARTICLE; CANCER GROWTH; CARCINOGENESIS; EMBRYO; GENE DELETION; GENE INACTIVATION; GENE LOSS; HK2 GENE; INTRACELLULAR SIGNALING; MALE; MALIGNANT TRANSFORMATION; MOUSE; NONHUMAN; PROSTATE CANCER; PROSTATE CANCER CELL LINE; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PTEN GENE; RNA STABILITY; RNA SYNTHESIS; RNA TRANSLATION; TUMOR SUPPRESSOR GENE; ANIMAL; DEFICIENCY; FIBROBLAST; GENETICS; GLYCOLYSIS; METABOLISM; PROSTATE TUMOR; PROTEIN SYNTHESIS; TUMOR CELL LINE;

ANIMALS; CARRIER PROTEINS; CELL LINE, TUMOR; FIBROBLASTS; GENE DELETION; GLYCOLYSIS; HEXOKINASE; MALE; MICE; MULTIPROTEIN COMPLEXES; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; PROTEIN BIOSYNTHESIS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; TOR SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84922503253     PISSN: None     EISSN: 22111247     Source Type: Journal    
DOI: 10.1016/j.celrep.2014.07.053     Document Type: Article

References (46)

1. Barbieri C.E., Baca S.C., Lawrence M.S., Demichelis F., Blattner M., Theurillat J.P., White T.A., Stojanov P., Van Allen E., Stransky N., et al. Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat. Genet. 2012, 44:685-689.
2. Bensaad K., Tsuruta A., Selak M.A., Vidal M.N., Nakano K., Bartrons R., Gottlieb E., Vousden K.H. TIGAR, a p53-inducible regulator of glycolysis and apoptosis. Cell 2006, 126:107-120.
3. Cairns P., Okami K., Halachmi S., Halachmi N., Esteller M., Herman J.G., Jen J., Isaacs W.B., Bova G.S., Sidransky D. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 1997, 57:4997-5000.
4. Chen Z., Trotman L.C., Shaffer D., Lin H.K., Dotan Z.A., Niki M., Koutcher J.A., Scher H.I., Ludwig T., Gerald W., et al. Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 2005, 436:725-730.
5. Chen M.L., Xu P.Z., Peng X.D., Chen W.S., Guzman G., Yang X., Di Cristofano A., Pandolfi P.P., Hay N. The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/- mice. Genes Dev. 2006, 20:1569-1574.
6. DeMarzo A.M., Nelson W.G., Isaacs W.B., Epstein J.I. Pathological and molecular aspects of prostate cancer. Lancet 2003, 361:955-964.
7. Fang M., Shen Z., Huang S., Zhao L., Chen S., Mak T.W., Wang X. The ER UDPase ENTPD5 promotes protein N-glycosylation, the Warburg effect, and proliferation in the PTEN pathway. Cell 2010, 143:711-724.
8. Fang R., Xiao T., Fang Z., Sun Y., Li F., Gao Y., Feng Y., Li L., Wang Y., Liu X., et al. MicroRNA-143 (miR-143) regulates cancer glycolysis via targeting hexokinase 2 gene. J.Biol. Chem. 2012, 287:23227-23235.
9. Grasso C.S., Wu Y.M., Robinson D.R., Cao X., Dhanasekaran S.M., Khan A.P., Quist M.J., Jing X., Lonigro R.J., Brenner J.C., et al. The mutational landscape of lethal castration-resistant prostate cancer. Nature 2012, 487:239-243.
10. Gray I.C., Phillips S.M., Lee S.J., Neoptolemos J.P., Weissenbach J., Spurr N.K. Loss of the chromosomal region 10q23-25 in prostate cancer. Cancer Res. 1995, 55:4800-4803.
11. Gregersen L.H., Jacobsen A., Frankel L.B., Wen J., Krogh A., Lund A.H. MicroRNA-143 down-regulates Hexokinase 2 in colon cancer cells. BMC Cancer 2012, 12:232.
12. Guertin D.A., Sabatini D.M. Defining the role of mTOR in cancer. Cancer Cell 2007, 12:9-22.
13. Haffner M.C., Mosbruger T., Esopi D.M., Fedor H., Heaphy C.M., Walker D.A., Adejola N., Gürel M., Hicks J., Meeker A.K., et al. Tracking the clonal origin of lethal prostate cancer. J.Clin. Invest. 2013, 123:4918-4922.
14. Hsieh A.C., Costa M., Zollo O., Davis C., Feldman M.E., Testa J.R., Meyuhas O., Shokat K.M., Ruggero D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E. Cancer Cell 2010, 17:249-261.
15. Hu W., Zhang C., Wu R., Sun Y., Levine A., Feng Z. Glutaminase 2, a novel p53 target gene regulating energy metabolism and antioxidant function. Proc. Natl. Acad. Sci. USA 2010, 107:7455-7460.
16. Jacinto E., Facchinetti V., Liu D., Soto N., Wei S., Jung S.Y., Huang Q., Qin J., Su B. SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell 2006, 127:125-137.
17. Jiang P., Du W., Wang X., Mancuso A., Gao X., Wu M., Yang X. p53 regulates biosynthesis through direct inactivation of glucose-6-phosphate dehydrogenase. Nat. Cell Biol. 2011, 13:310-316.
18. Jiang S., Zhang L.F., Zhang H.W., Hu S., Lu M.H., Liang S., Li B., Li Y., Li D., Wang E.D., Liu M.F. A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J. 2012, 31:1985-1998.
19. Jonkers J., Meuwissen R., van der Gulden H., Peterse H., van der Valk M., Berns A. Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat. Genet. 2001, 29:418-425.
20. Kondoh H., Lleonart M.E., Gil J., Wang J., Degan P., Peters G., Martinez D., Carnero A., Beach D. Glycolytic enzymes can modulate cellular life span. Cancer Res. 2005, 65:177-185.
21. Laplante M., Sabatini D.M. mTOR signaling in growth control and disease. Cell 2012, 149:274-293.
22. Levine A.J., Puzio-Kuter A.M. The control of the metabolic switch in cancers by oncogenes and tumor suppressor genes. Science 2010, 330:1340-1344.
23. Lunardi A., Ala U., Epping M.T., Salmena L., Clohessy J.G., Webster K.A., Wang G., Mazzucchelli R., Bianconi M., Stack E.C., et al. A co-clinical approach identifies mechanisms and potential therapies for androgen deprivation resistance in prostate cancer. Nat. Genet. 2013, 45:747-755.
24. Majewski N., Nogueira V., Bhaskar P., Coy P.E., Skeen J.E., Gottlob K., Chandel N.S., Thompson C.B., Robey R.B., Hay N. Hexokinase-mitochondria interaction mediated by Akt is required to inhibit apoptosis in the presence or absence of Bax and Bak. Mol. Cell 2004, 16:819-830.
25. Markert E.K., Mizuno H., Vazquez A., Levine A.J. Molecular classification of prostate cancer using curated expression signatures. Proc. Natl. Acad. Sci. USA 2011, 108:21276-21281.
26. Mathupala S.P., Heese C., Pedersen P.L. Glucose catabolism in cancer cells. The type II hexokinase promoter contains functionally active response elements for the tumor suppressor p53. J.Biol. Chem. 1997, 272:22776-22780.
27. Mathupala S.P., Rempel A., Pedersen P.L. Glucose catabolism in cancer cells: identification and characterization of a marked activation response of the type II hexokinase gene to hypoxic conditions. J.Biol. Chem. 2001, 276:43407-43412.
28. Matoba S., Kang J.G., Patino W.D., Wragg A., Boehm M., Gavrilova O., Hurley P.J., Bunz F., Hwang P.M. p53 regulates mitochondrial respiration. Science 2006, 312:1650-1653.
29. Muller P.A., Vousden K.H. Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 2014, 25:304-317.
30. Navone N.M., Labate M.E., Troncoso P., Pisters L.L., Conti C.J., von Eschenbach A.C., Logothetis C.J. p53 mutations in prostate cancer bone metastases suggest that selected p53 mutants in the primary site define foci with metastatic potential. J.Urol. 1999, 161:304-308.
31. Patra K.C., Wang Q., Bhaskar P.T., Miller L., Wang Z., Wheaton W., Chandel N., Laakso M., Muller W.J., Allen E.L., et al. Hexokinase 2 is required for tumor initiation and maintenance and its systemic deletion is therapeutic in mouse models of cancer. Cancer Cell 2013, 24:213-228.
32. Peschiaroli A., Giacobbe A., Formosa A., Markert E.K., Bongiorno-Borbone L., Levine A.J., Candi E., D'Alessandro A., Zolla L., Finazzi Agrò A., Melino G. miR-143 regulates hexokinase 2 expression in cancer cells. Oncogene 2013, 32:797-802.
33. Roberts D.J., Tan-Sah V.P., Smith J.M., Miyamoto S. Akt phosphorylates HK-II at Thr-473 and increases mitochondrial HK-II association to protect cardiomyocytes. J.Biol. Chem. 2013, 288:23798-23806.
34. Sarbassov D.D., Guertin D.A., Ali S.M., Sabatini D.M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005, 307:1098-1101.
35. Shen M.M., Abate-Shen C. Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev. 2010, 24:1967-2000.
36. Song M.S., Salmena L., Pandolfi P.P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 2012, 13:283-296.
37. Sun Q., Chen X., Ma J., Peng H., Wang F., Zha X., Wang Y., Jing Y., Yang H., Chen R., et al. Mammalian target of rapamycin up-regulation of pyruvate kinase isoenzyme type M2 is critical for aerobic glycolysis and tumor growth. Proc. Natl. Acad. Sci. USA 2011, 108:4129-4134.
38. Suzuki H., Freije D., Nusskern D.R., Okami K., Cairns P., Sidransky D., Isaacs W.B., Bova G.S. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 1998, 58:204-209.
39. Suzuki H.I., Yamagata K., Sugimoto K., Iwamoto T., Kato S., Miyazono K. Modulation of microRNA processing by p53. Nature 2009, 460:529-533.
40. Suzuki S., Tanaka T., Poyurovsky M.V., Nagano H., Mayama T., Ohkubo S., Lokshin M., Hosokawa H., Nakayama T., Suzuki Y., et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc. Natl. Acad. Sci. USA 2010, 107:7461-7466.
41. Whang Y.E., Wu X., Suzuki H., Reiter R.E., Tran C., Vessella R.L., Said J.W., Isaacs W.B., Sawyers C.L. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA 1998, 95:5246-5250.
42. Wilson J.E. Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function. J.Exp. Biol. 2003, 206:2049-2057.
43. Wolf A., Agnihotri S., Micallef J., Mukherjee J., Sabha N., Cairns R., Hawkins C., Guha A. Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J.Exp. Med. 2011, 208:313-326.
44. Wu X., Wu J., Huang J., Powell W.C., Zhang J., Matusik R.J., Sangiorgi F.O., Maxson R.E., Sucov H.M., Roy-Burman P. Generation of a prostate epithelial cell-specific Cre transgenic mouse model for tissue-specific gene ablation. Mech. Dev. 2001, 101:61-69.
45. Zhang C., Lin M., Wu R., Wang X., Yang B., Levine A.J., Hu W., Feng Z. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. Proc. Natl. Acad. Sci. USA 2011, 108:16259-16264.
46. Zheng H., Ying H., Yan H., Kimmelman A.C., Hiller D.J., Chen A.J., Perry S.R., Tonon G., Chu G.C., Ding Z., et al. p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. Nature 2008, 455:1129-1133.